Phase 3 Recruiting Academic/Other
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…
Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in Florida: - AdventHealth Altamonte — Altamonte Springs, Florida
- Mount Sinai Comprehensive Cancer Center at Aventura — Aventura, Florida
- UM Sylvester Comprehensive Cancer Center at Aventura — Aventura, Florida
- Florida Cancer Specialists - Bradenton Cancer Center — Bradenton, Florida
- Morton Plant Hospital — Clearwater, Florida
Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in Florida: - Mount Sinai Comprehensive Cancer Center at Aventura — Aventura, Florida
- Morton Plant Hospital — Clearwater, Florida
- Broward Health North — Deerfield Beach, Florida
- Holy Cross Hospital — Fort Lauderdale, Florida
- Broward Health Medical Center — Fort Lauderdale, Florida
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of continuation of treatment with pembrolizumab (usual approach) to observation only at preventing cancer from coming back in patients with early-stage triple-negative breast cancer (TNBC) who achie…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05812807
Sites in Florida: - AdventHealth Altamonte — Altamonte Springs, Florida
- Schulze Family Foundation Cancer Clinic - Bonita Health Center — Bonita Springs, Florida
- Morton Plant Hospital — Clearwater, Florida
- Broward Health Medical Center — Fort Lauderdale, Florida
- Regional Cancer Center-Lee Memorial Health System — Fort Myers, Florida
Phase 3 Recruiting Academic/Other
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radi…
Sponsor: NRG Oncology
NCT ID: NCT04852887
Sites in Florida: - AdventHealth Altamonte — Altamonte Springs, Florida
- GenesisCare USA - Aventura FP — Aventura, Florida
- GenesisCare USA - Aventura — Aventura, Florida
- Mount Sinai Comprehensive Cancer Center at Aventura — Aventura, Florida
- Florida Cancer Specialists - Bradenton Cancer Center — Bradenton, Florida
Phase 3 Recruiting Network
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in Florida: - Broward Health Medical Center — Fort Lauderdale, Florida
- Mount Sinai Medical Center — Miami Beach, Florida
- Moffitt Cancer Center — Tampa, Florida
- Cleveland Clinic-Weston — Weston, Florida
Phase 3 Recruiting Academic/Other
NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …
Sponsor: NRG Oncology
NCT ID: NCT06748222
Sites in Florida: - Halifax Health Cancer Center for Hope - Daytona Beach — Daytona Beach, Florida
- UF Health Cancer Institute - Gainesville — Gainesville, Florida
- Mayo Clinic in Florida — Jacksonville, Florida
- Tallahassee Memorial HealthCare — Tallahassee, Florida
Phase 3 Recruiting NIH
This phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone therapy plus ribociclib for the treatment of patients with high anatomic stage breast cancer with low risk of the cancer ret…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07391774
Sites in Florida: - The Watson Clinic — Lakeland, Florida
Phase 3 Recruiting Industry
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early b…
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT06492616
Sites in Florida: - Boca Raton Regional Hospital (BRRH) - Lynn Cancer Institute — Boca Raton, Florida
- Florida Cancer Specialists — Fort Myers, Florida
- Mayo Clinic — Jacksonville, Florida
- Helios Clinical — Lakeland, Florida
- Miami Cancer Institute at Baptist Health Inc. — Miami, Florida
Phase 3 Recruiting Industry
The purpose of the study is to assess the efficacy and safety of the addition of Tersolisib (LY4064809/STX-478) to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal growth factor recept…
Sponsor: Eli Lilly and Company
NCT ID: NCT07174336
Sites in Florida: - AdventHealth Altamonte Springs — Altamonte Springs, Florida
- Clermont Oncology Center — Clermont, Florida
- Florida Oncology & Hematology — Fort Myers, Florida
- Mayo Clinic in Florida — Jacksonville, Florida
- University of Miami Hospital and Clinics, Sylvester Cancer Center — Miami, Florida
Phase 3 Recruiting Industry
This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlimab\], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metasta…
Sponsor: BriaCell Therapeutics Corporation
NCT ID: NCT06072612
Sites in Florida: - University of Miami _SCCC - Aventura — Aventura, Florida
- University of Miami-SCCC-Lennar — Coral Gables, Florida
- University of Miami_SCCC-Coral Springs — Coral Springs, Florida
- University of Miami Hospital and Clinics - Deerfield Beach — Deerfield Beach, Florida
- University of Miami_SCCC-Hollywood — Hollywood, Florida
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in th…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06966700
Sites in Florida: - AdventHealth Medical Group Oncology and Hematology at Altamonte ( Site 0044) — Altamonte Springs, Florida
- Florida Cancer Specialists - South ( Site 7004) — Fort Myers, Florida
- Bioresearch Partner ( Site 0072) — Hialeah, Florida
- Mayo Clinic Hospital ( Site 0013) — Jacksonville, Florida
- Florida Cancer Specialists - North ( Site 7002) — St. Petersburg, Florida
Phase 3 Recruiting Industry
This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participant…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06790693
Sites in Florida: - Cancer Specialists of North Florida - Jacksonville — Jacksonville, Florida
- Tallahassee Memorial HealthCare — Tallahassee, Florida
- Moffitt Cancer Center-McKinley Campus — Tampa, Florida
- Cleveland Clinic Florida — Weston, Florida
Phase 3 Recruiting Industry
This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.
Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT07085767
Sites in Florida: - Clinical Trial Site — Tampa, Florida
Phase 3 Recruiting Industry
This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutati…
Sponsor: Relay Therapeutics, Inc.
NCT ID: NCT06982521
Sites in Florida: - AdventHealth — Altamonte Springs, Florida
- Florida Cancer Specialists-South — Fort Myers, Florida
- Cancer Care Centers of Brevard, Inc — Palm Bay, Florida
Phase 3 Recruiting Industry
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who ha…
Sponsor: LeonaBio
NCT ID: NCT05696626
Sites in Florida: - Mayo Clinic - Jacksonville — Jacksonville, Florida
- Miami Cancer Institute — Miami, Florida
- Miami Cancer Institute Plantation — Plantation, Florida
Phase 3 Recruiting Industry
A study to assess the efficacy and safety of Dato-DXd in the pre-chemotherapy setting for patients with metastatic HR-positive, HER2 IHC 0 breast cancer.
Sponsor: AstraZeneca
NCT ID: NCT07205822
Sites in Florida: - Research Site — Largo, Florida
Phase 3 Recruiting Academic/Other
This randomized, multi-institutional phase III trial evaluates whether routine surveillance brain MRI every 6 months improves detection and treatment characteristics of brain metastases in neurologically asymptomatic patients with stage IV…
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
NCT ID: NCT07357298
Sites in Florida: - Baptist Health South Florida — Miami, Florida
- Moffitt Cancer Center — Tampa, Florida
Phase 2 Recruiting Academic/Other
This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of …
Sponsor: Dana-Farber Cancer Institute
NCT ID: NCT04893109
Sites in Florida: - Miami Cancer Institute/Baptist Hospital of Miami — Miami, Florida
- Miami Cancer Institute - Plantation (MCIP) — Plantation, Florida
Phase 1, Phase 2 Recruiting Industry
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…
Sponsor: Genmab
NCT ID: NCT05579366
Sites in Florida: - USOR Florida Cancer Specialists South — Fort Myers, Florida
- USOR Florida Cancer Specialists North — St. Petersburg, Florida
- USOR Florida Cancer Specialists East — West Palm Beach, Florida
Phase 2 Recruiting Industry
PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) …
Sponsor: Puma Biotechnology, Inc.
NCT ID: NCT06369285
Sites in Florida: - Mayo Clinic Florida — Jacksonville, Florida
- Cancer Specialists of North Florida — Jacksonville, Florida
- Moffitt Cancer Center — Tampa, Florida
Phase 2 Recruiting Academic/Other
The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with ductal cell carcinoma in situ (DCIS), an early stage of breast cancer, can be an effective management of the disease. Partic…
Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT06075953
Sites in Florida: - Moffitt Cancer Center — Tampa, Florida
Phase 1, Phase 2 Recruiting Industry
Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with…
Sponsor: Eli Lilly and Company
NCT ID: NCT05768139
Sites in Florida: - Florida Cancer Specialists ORLANDO/DDU — Lake Mary, Florida
- Moffitt Cancer Center — Tampa, Florida
Phase 2 Recruiting Industry
The Substudy Protocol ASPEN-09-03 is a Phase 2, single-arm, multicenter study evaluating the efficacy, safety, and tolerability of evorpacept in combination with trastuzumab and chemotherapy in participants with HER2-positive metastatic br…
Sponsor: ALX Oncology Inc.
NCT ID: NCT07007559
Sites in Florida: - Mayo Clinic — Jacksonville, Florida
- Sylvester Comprehensive Cancer Center — Miami, Florida
- Moffitt Cancer Center — Tampa, Florida
Phase 1, Phase 2 Recruiting Industry
This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible s…
Sponsor: 858 Therapeutics, Inc.
NCT ID: NCT06395519
Sites in Florida: - Mayo Clinic — Jacksonville, Florida
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06618287
Sites in Florida: - University of Miami Hospital and Clinics, Sylvester Cancer Center — Miami, Florida